HCW Biologics (HCWB) vs Purple Biotech (PPBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
HCW Biologics is the larger company by market cap ($2.4 million vs $1.9 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCWB | PPBT |
|---|---|---|
| Share price | $0.7491 | $1.53 |
| Market cap | $2.35M | $1.86M |
| 1-day change | +1.90% | -4.09% |
| EPS (TTM) | $-9.09 | $-47.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $54.23K | — |
| Revenue growth (YoY) | -97.89% | — |
| Net income (latest FY) | $-7.96M | $-26.39M |
| Gross margin | 20.00% | — |
| Operating margin | -24270.74% | — |
| Net margin | -14677.14% | — |
| 52-week high | $23.94 | $8.90 |
| 52-week low | $0.70 | $0.91 |
| Distance from 52-week high | -96.87% | -82.87% |
| Analyst consensus | buy | none |
| Avg. price target upside | +6307.69% | +1014.75% |
| Average volume | 379.38K | 1.26M |
| Shares outstanding | 3.14M | 1.22M |
| Employees | 35 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About HCW Biologics
HCWB stock →HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
About Purple Biotech
PPBT stock →Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
HCWB vs PPBT FAQ
Which is bigger, HCW Biologics or Purple Biotech?
HCW Biologics (HCWB) is larger, with a market capitalization of $2.35M compared with $1.86M for Purple Biotech (PPBT).
Are HCW Biologics and Purple Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.